Last Updated : October 30, 2024
Details
FilesGeneric Name:
Enzalutamide
Project Status:
Complete
Therapeutic Area:
Genito-urinary cancer (prostate cancer)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0366-000
Call for patient/clinician input closed:
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
For the treatment of
patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with
biochemical recurrence at high risk of metastasis (high-risk BCR)
| Submission received | April 30, 2024 |
|---|---|
| Review initiated | May 01, 2024 |
| Expert committee meeting (initial) | September 19, 2024 |
| Draft recommendation posted for stakeholder feedback | October 17, 2024 |
| End of feedback period | October 31, 2024 |
| Final recommendation posted | - |
| CADTH review report(s) posted | October 28, 2024 |
Files
Last Updated : October 30, 2024